Patent ID: 11857600
Assignee: GPCR THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. The method of claim 2, wherein the CXCR4-HRH1 heteromer has enhanced amount of calcium mobilization, such that:
a) either the CXCR4 or the HRH1 in an individual protomer context in a cancer cell, upon co-stimulation with CXCL12 and a selective HRH1 agonist, results in a calcium mobilization amount that is equal to or less than the sum of calcium mobilization amounts resulting from single agonist stimulation with either the CXCL12 or the HRH1 agonist; and
b) the CXCR4-HRH1 heteromer exhibits an enhanced calcium mobilization upon co-stimulation with the CXCL12 and the selective HRH1 agonist relative to the sum of calcium mobilization amounts resulting from single agonist stimulation with either the CXCL12 or the selective HRH1 agonist;
as determined via a calcium mobilization assay.